First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer. (October 2017)

• Record Type: Journal Article
• Authors: Araki, Kazuhiro; Fukada, Ippei; Yanagi, Hiroyo; Kobayashi, Kokoro; Shibayama, Tomoko; Horii, Rie; Takahashi, Shunji; Akiyama, Futoshi; Ohno, Shinji; Ito, Yoshinori
• Is Part Of: Breast. Volume 35(2017)
• Page Start: 78
• Page End: 84
• Publication Date: 2017-10
• Subjects: Eribulin -- HER2-positive advanced breast cancer -- Non-taxane microtubule dynamic inhibitor -- Pertuzumab -- Trastuzumab; Breast -- Diseases -- Periodicals; Breast -- Tumors -- Periodicals; Breast -- Periodicals; Electronic journals; Periodicals; 616
• DOI: 10.1016/j.breast.2017.06.015
• Languages: English
• ISSNs: 0960-9776

Abstract

Abstract: Background: The efficacy and safety of continuing multiple anti-HER2 therapies in advanced breast cancer (ABC) patients remains unclear. This study investigated eribulin in combination with pertuzumab and trastuzumab for both taxane- and trastuzumab-pretreated HER2-positive ABC patients. Methods: In a single-institute, single-arm, open-label, phase II trial, HER2-positive ABC patients who had previously received taxanes and trastuzumab were treated with eribulin in combination with pertuzumab and trastuzumab. The pharmacokinetics of eribulin in this combination were assessed in 6 patients. Tumor assessments were conducted every 6 weeks for the first 6 cycles and every 12 weeks thereafter. The primary endpoint was objective response rate (ORR). Results: A total of 30 patients (median age, 58 years; range, 31–76) were enrolled, with a median number of previous chemotherapy regimens of 3.5 (range: 1–9) in the metastatic setting. Pharmacokinetic parameters of eribulin in this combination were similar to previous reports of eribulin monotherapy. ORR was 34.8% (95% CI: 16.4–57.3, n = 23), and median progression-free survival was 42.6 weeks (95% CI: 20.3–51.9, n = 30). Clinical benefit rate was 60.9% (95% CI: 16.4–57.3). The most common grade 3/4 adverse event was neutropenia in 20 patients (66.7%). A dose reduction of eribulin was required in 27 patients due to adverse events, particularly grade 3 neutropenia. Conclusions: Eribulin in combination with pertuzumab and trastuzumab was well tolerated in heavily pretreated patients. Eribulin may be a viable treatment option when used in combination with pertuzumab and trastuzumab for HER2-positive ABC patients (UMIN Clinical Trial Registry identification number, UMIN000012375). Highlights: Eribulin plus pertuzumab and trastuzumab was tolerated in HER2+ breast cancer. Eribulin may be a viable treatment option with pertuzumab and trastuzumab. Objective response rate was 34.8%. Median progression-free survival was 42.6 weeks. Clinical benefit rate was 60.9%.